Although other studies have suggested that TYMS expression holds potential as a predictor of responsiveness to pemetrexed treatment in advanced cancer patients [3, 6, 9, 18], prospective studies are necessary to confirm these findings in NSCLC patients. This evidence concerns the gene TYMS and cancer.